| scholarly article | Q13442814 |
| P50 | author | Anke Henning | Q37617177 |
| Paul Steendijk | Q51590066 | ||
| Houman Ashrafian | Q55127377 | ||
| P2093 | author name string | Kiran Patel | |
| Girish Dwivedi | |||
| Michael Frenneaux | |||
| Thanh T Phan | |||
| Gnanadevan Mahadevan | |||
| Ganesh Nallur Shivu | |||
| Ibrar Ahmed | |||
| Khalid Abozguia | |||
| Lynne Williams | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| ejection fraction | Q641303 | ||
| Heart failure with preserved ejection fraction | Q3799239 | ||
| P304 | page(s) | 402-409 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. | |
| P478 | volume | 54 |
| Q100559245 | A 1H-NMR approach to myocardial energetics |
| Q47105229 | A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function |
| Q26850196 | A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation |
| Q52919323 | A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. |
| Q38267856 | A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group |
| Q39647469 | Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. |
| Q47648074 | Afterload-induced diastolic dysfunction contributes to high filling pressures in experimental heart failure with preserved ejection fraction. |
| Q47338830 | An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology |
| Q36721721 | Cardiac Remodeling, Adaptations and Associated Myocardial Mechanics in Hypertensive Heart Diseases |
| Q38057699 | Cardiac metabolism in hypertrophy and heart failure: implications for therapy |
| Q37380080 | Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction |
| Q28070075 | Cardiometabolic Syndrome and Increased Risk of Heart Failure |
| Q102053976 | Cardioprotective effects of short-term empagliflozin treatment in db/db mice |
| Q38285243 | Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fraction |
| Q50611098 | Changes of ventricular and peripheral performance in patients with heart failure and normal ejection fraction: insights from ergometry stress echocardiography. |
| Q38427211 | Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes |
| Q35072520 | Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction |
| Q84976122 | Culprit Mechanism(s) for Exercise Intolerance in Heart Failure With Normal Ejection Fraction |
| Q55182135 | Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. |
| Q37656346 | Current controversies in heart failure with a preserved ejection fraction |
| Q37292234 | Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? |
| Q50152159 | Decreased ATP production and myocardial contractile reserve in metabolic heart disease. |
| Q61650910 | Deleterious Effects of Cold Air Inhalation on Coronary Physiological Indices in Patients With Obstructive Coronary Artery Disease |
| Q30465751 | Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction |
| Q64103453 | Diastolic Ventricular Interaction in Heart Failure With Preserved Ejection Fraction |
| Q34816125 | Diastolic dysfunction is associated with an increased risk of contrast-induced nephropathy: a retrospective cohort study |
| Q37156981 | Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction |
| Q57293272 | Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials |
| Q37299336 | Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study |
| Q53132786 | Echocardiographic particle image velocimetry for the evaluation of diastolic function in hypertrophic nonobstructive cardiomyopathy. |
| Q36266675 | Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction |
| Q36469075 | Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study |
| Q35630046 | Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction |
| Q37143327 | Exercise Intolerance In Heart Failure With Preserved Ejection Fraction |
| Q34623775 | Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction |
| Q38906962 | Exercise training reverses age-induced diastolic dysfunction and restores coronary microvascular function |
| Q37699474 | Expert consensus document: Mitochondrial function as a therapeutic target in heart failure |
| Q34178646 | Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction |
| Q88711708 | Haemodynamics of Heart Failure With Preserved Ejection Fraction: A Clinical Perspective |
| Q38672337 | Heart Failure with Preserved Ejection Fraction in Older Adults |
| Q38592514 | Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review |
| Q30417324 | Heart failure with normal ejection fraction: a growing pandemic |
| Q27024008 | Heart failure with preserved ejection fraction |
| Q42573531 | Heart failure with preserved ejection fraction failure to preserve, failure of reserve, and failure on the compliance curve |
| Q37633991 | Heart failure with preserved ejection fraction in the elderly: scope of the problem |
| Q30420528 | Heart failure with preserved ejection fraction. |
| Q47822589 | Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG). |
| Q38217344 | Heart failure with preserved ejection fraction: current understandings and challenges |
| Q24595118 | Heart failure with preserved ejection fraction: emerging drug strategies |
| Q27000263 | Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies |
| Q37725106 | Heart failure with preserved ejection fraction: pathophysiology and emerging therapies |
| Q34664894 | Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment |
| Q88871551 | Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction |
| Q41225769 | Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction |
| Q90059150 | How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) |
| Q35115055 | Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction |
| Q42662622 | Increased left ventricular stiffness impairs exercise capacity in patients with heart failure symptoms despite normal left ventricular ejection fraction |
| Q56957016 | Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life |
| Q90725943 | Lead aVR is a predictor for mortality in heart failure with preserved ejection fraction |
| Q39475312 | Loss of myocardial retinoic acid receptor α induces diastolic dysfunction by promoting intracellular oxidative stress and calcium mishandling in adult mice |
| Q38502630 | MRS: a noninvasive window into cardiac metabolism. |
| Q37688176 | Magnetic resonance spectroscopy in myocardial disease |
| Q38743215 | Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions |
| Q92267248 | Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction |
| Q88169588 | Mitochondrial Function in Non-ischemic Heart Failure |
| Q90698376 | Myocardial Energetics in Heart Failure With Preserved Ejection Fraction |
| Q89344374 | Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction |
| Q96131186 | Novel Echocardiography-Derived Left Ventricular Stiffness Index in Low-Flow Versus Normal-Flow Severe Aortic Stenosis with Preserved Left Ventricular Ejection Fraction |
| Q40963394 | Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction |
| Q37893956 | Novel therapeutic targets for the treatment of heart failure. |
| Q38988016 | Partial Adenosine A1 Agonist in Heart Failure |
| Q41927225 | PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design |
| Q33782408 | Phosphorylation of cardiac troponin I at protein kinase C site threonine 144 depresses cooperative activation of thin filaments |
| Q91871826 | Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial |
| Q40217312 | Prognostic impact of diastolic dysfunction in systolic heart failure-A cross-project analysis from the German Competence Network Heart Failure. |
| Q44710575 | Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction |
| Q38844736 | Quantitative MRI biomarkers to characterize regional left ventricular perfusion and function in nonhuman primates during dobutamine-induced stress: A reproducibility and reliability study |
| Q39078019 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome |
| Q40295899 | Relation of Red Cell Distribution Width to Left Ventricular End-Diastolic Pressure and Mortality in Patients With and Without Heart Failure |
| Q49884503 | Relationship between skeletal muscle mass and cardiac function during exercise in community-dwelling older adults |
| Q58705696 | Relationship of Transmural Variations in Myofiber Contractility to Left Ventricular Ejection Fraction: Implications for Modeling Heart Failure Phenotype With Preserved Ejection Fraction |
| Q37477647 | Similarities and Differences between the Pathogenesis and Pathophysiology of Diastolic and Systolic Heart Failure |
| Q30381147 | Spatial Orientation and Morphology of the Pulmonary Artery: Relevance to Optimising Design and Positioning of a Continuous Pressure Monitoring Device. |
| Q42478668 | Synergistic role of ADP and Ca(2+) in diastolic myocardial stiffness |
| Q60934988 | The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study |
| Q42415584 | The pathophysiology of diastolic heart failure |
| Q38222648 | The pathophysiology of heart failure with preserved ejection fraction. |
| Q90253350 | TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study |
| Q26766590 | Understanding heart failure with preserved ejection fraction: where are we today? |
| Q97645771 | Use of cardiac magnetic resonance to detect changes in metabolism in heart failure |
| Q26828760 | Use of metformin in diseases of aging |
| Q91862018 | Use of speckle tracking to assess heart failure with preserved ejection fraction |
| Q28083350 | What can we learn about treating heart failure from the heart's response to acute exercise? Focus on the coronary microcirculation |
| Q37350630 | Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction |
| Q52869074 | [New therapy concepts for heart failure with preserved ejection fraction]. |
Search more.